Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of EXEnatide on Glycemic Control and Weight Over 26 Weeks in Continuous Subcutaneous Insulin Infusion (CSII) Treated Patients With Type 2 Diabetes : a Phase 2/3 Double Blind randoMized Placebo-controlled Trial.

NCT01140893 is registered in ClinicalTrials.gov with University Hospital, Caen as lead sponsor.

NCT NCT01140893
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01140893 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of EXEnatide on Glycemic Control and Weight Over 26 Weeks in Continuous Subcutaneous Insulin Infusion (CSII) Treated Patients With Type 2 Diabetes : a Phase 2/3 Double Blind randoMized Placebo-controlled Trial.
Lead sponsor
University Hospital, Caen
Phase
Phase 2/3
Overall status
Unknown status
Start date
November 30, 2010
Completion date
Not reported
Enrollment
110 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes